Cargando…
Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin
PROteolysis TArgeting Chimeras (PROTACs) induce targeted protein degradation by hijacking the intracellular ubiquitin proteasome system, thus emerging as a new strategy for drug development. However, most PROTACs generated lack cell-type selectivity and are poorly soluble in water. To address this d...
Autores principales: | Zhang, Lin, Li, Ling, Wang, Xia, Liu, Huimin, Zhang, Yibin, Xie, Tiantian, Zhang, Hui, Li, Xiaodong, Peng, Tianhuan, Sun, Xing, Dai, Jing, Liu, Jing, Wu, Wencan, Ye, Mao, Tan, Weihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535278/ https://www.ncbi.nlm.nih.gov/pubmed/36250201 http://dx.doi.org/10.1016/j.omtn.2022.09.008 |
Ejemplares similares
-
Elucidation of CKAP4-remodeled cell mechanics in driving metastasis of bladder cancer through aptamer-based target discovery
por: Sun, Xing, et al.
Publicado: (2022) -
Insights into the binding mode of AS1411 aptamer to nucleolin
por: Bie, Lihua, et al.
Publicado: (2022) -
DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022) -
Anti-nucleolin aptamer AS1411: an advancing therapeutic
por: Van den Avont, Alexander, et al.
Publicado: (2023) -
AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation
por: Iturriaga-Goyon, Emilio, et al.
Publicado: (2021)